CTNI-77 - Post-Progression Treatment after VAL-083 with radiation in newly diagnosed GBM MGMT unmethylated patients

Friday, November 17, 2023

7:30 PM – 9:30 PM PT

Location: Exhibit Hall A/B

Author(s)

CG

Cheng-chen Guo

Sun Yat-sen University Cancer Center
Guangzhou, China (People's Republic)
QY

Qun-ying Yang

Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, United States
SX

Shao-yan Xi

Sun Yat-sen University Cancer Center
Guangzhou, United States
yL

yi-xiang Liao

Sun Yat-sen University Cancer Center
Guangzhou, United States
De-pei Li

Sun Yat-sen University Cancer Center
Guangzhou, United States
XJ

Xiao-bing Jiang

Sun Yat-sen University Cancer Center
Guangzhou, United States
YC

Yin-sheng Chen

Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, United States
CK

Chao Ke

Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, United States
KS

Ke Sai

Sun Yat-Sun University Cancer Center
Guangzhou, Guangdong, China (People's Republic)
RS

Richard Schwartz

Kintara Therapeutics
Menlo Park, California, United States

Poster Presenter(s)

John M. Langlands

Kintara Therapeutics
Vancouver, British Columbia, Canada

Author(s)

DB

Dennis Brown

Kintara Therapeutics
Menlo Park, California, United States
Zhongping Chen

Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China (People's Republic)

VAL-083 is a novel DNA targeting agent that induces inter-strand DNA cross-links at N⁷-guanine, leading to DNA double-strand breaks and cell death. In vitro and in vivo studies have demonstrated VAL-083 circumvents MGMT-mediated chemoresistance and thus differentiates it from other therapies used in the treatment of GBM, including temozolomide (TMZ). VAL-083 also acts as a radiosensitizer against GBM cancer stem cells in vitro. A Phase 2 study was conducted to evaluate the safety and tolerability of VAL-083 when administered concurrently with radiation therapy (RT) in newly diagnosed MGMT-unmethylated GBM. Stage 1 was a dose-escalation to confirm the dose of VAL-083 in this setting; VAL-083 at 20, 30, or 40 mg/m²/day x 3 days every 21 days in combination with standard radiation treatment (RT) (2 Gy/day, 5 days/week for 6 weeks). Stage 2 was an expansion phase to enroll up to 20 additional patients at the 30 mg/m²/day of VAL-083 with RT. A total of 29 patients were enrolled in the study and completed treatment, with 25 patients receiving 30 mg/m²/day VAL-083.